In this retrospective cohort study carried out in an area with a high incidence of EGFR mutation-positive NSCLC and using a modern radiotherapy technique, PORT was associated with an improved DFS rate in patients with R0 pN2-stage III NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.